D-K₆L₉ Peptide Combination with IL-12 Inhibits the Recurrence of Tumors in Mice

Tomasz Cichon · Ryszard Smolarczyk · Sybilla Matuszczak · Magdalena Barczyk · Magdalena Jarosz · Stanisław Szala

Received: 28 September 2012 / Accepted: 11 October 2013 / Published online: 2 February 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract  D-K₆L₉ peptide is bound by phosphatidylserine and induces necrosis in cancer cells. In our therapeutic experience, this peptide, when administered directly into B16-F10 murine melanoma tumors, inhibited their growth. Cessation of therapy results, however, in tumor relapse. We aimed at developing a combined therapy involving D-K₆L₉ and additional factors that would yield complete elimination of tumor cells in experimental animals. To this purpose, we employed glycyrrhizin, an inhibitor of HMGB1 protein, BP1 peptide and interleukin (IL)-12. Glycyrrhizin or BP1, when combined with D-K₆L₉, inhibits growth of primary tumors only during the period of their administration. A long-term tumor growth inhibitory effect was obtained only in combining D-K₆L₉ with IL-12. At 2 months following therapy cessation, 60 % of animals were alive. Prolonged survival was noted in mice bearing B16-F10 tumors as well as in mice bearing C26 colon carcinoma tumors.

Keywords  Peptide D-K₆L₉ · Peptide BP1 · Glycyrrhizin · IL-12 · Anticancer therapy

Introduction

Peptides used in anticancer therapy kill cancer cells by destroying their cell or mitochondrial membranes. D-K₆L₉ is an example of cell membrane-acting peptide which triggers necrosis of cancer cells (Papo et al. 2004). D-K₆L₉ is a molecule in which 1/3 of its natural aminoacid sequence has been replaced with diastereoisomers. Introduction of D aminoacids increases stability of this peptide in other organisms as it makes proteolysis more difficult and increases peptide selectivity (Papo et al. 2004). D-K₆L₉ features both hydrophobic aminoacids (leucine) and hydrophilic ones (lysine), which make it an amphipathic molecule. In aqueous solutions, this peptide does not preserve an ordered secondary structure, whereas after attachment to the lipid bilayer it adopts α-helical conformation (Papo and Shai 2003). It is preferentially bound by membranes rich in negatively charged acidic phospholipids (Papo et al. 2004), an augmented number of which are found in cancer cell membranes (Mader and Hoskin 2006). The peptide is bound by phosphatidylserine present in the outer membrane of the bilayer (Papo et al. 2006). The peptide is bound until it reaches threshold concentration upon which the membrane is

Abbreviations

D-K₆L₉  Peptide-Ac[D(K₆L₉)]NH₂
BP1  Peptide-(SHRYRLAIQLHASDSSSSCV)
B16-F10  Murine melanoma cells
C26  Colon carcinoma cell
CSC  Cancer stem cells
HMGB1  High-mobility group box-1 protein
NK  Natural killer cells
VEGR  Vascular-endothelial growth receptor
PIGF  Placenta growth factor
IL-12  Interleukin-12
PBS⁻  Physiological buffered saline
RPMI 1640  Cell culture medium

Arch. Immunol. Ther. Exp. (2014) 62:341–351
DOI 10.1007/s00005-014-0268-z

© 2014 The Author(s).
This article is published with open access at Springerlink.com

T. Cichoń (✉) · R. Smolarczyk · S. Matuszczak · M. Barczyk · M. Jarosz · S. Szala
Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeże Armii Krajowej 15, 44-101 Gliwice, Poland
E-mail: ttcichon@io.gliwice.pl

123
depolarized and perforated causing cell death (Papo et al. 2004).

Therapeutic use of necrosis-triggering agents has its advantages and limitations. Among the most important factors released from necrotized cells is HMGB1 protein (Ellerman et al. 2007; Tang et al. 2011). Extracellular HMGB1 mediates chronic inflammatory condition, formation of new tumor microenvironment and angiogenesis. In other words, it facilitates tumor regrowth (Campana et al. 2008; Tang et al. 2010; Yang et al. 2005). On the other hand, inflammatory condition induced by HMGB1 and stimulation of antigen-presenting cell (APC) maturation can trigger immune response against cancer cells (Rovere-Querini et al. 2004; Zhu et al. 2010).

We tried to develop a combination therapy that would involve, besides D-K6L9, also other factors that would together totally destroy or inhibit B16-F10 melanoma tumors in experimental animals. Since surviving cancer cells and released HMGB1 protein can be responsible for tumor relapse, the proposed therapy involved factors that destroy the remnant cancer cells and that inhibit HMGB1.

HMGB1 inhibitors comprise specific antibodies, HMGB1 protein A box (Wang et al. 2012; Yang and Tracey 2010) or low-molecular compounds such as glycyrrhizin which inhibits HMGB1 following its release into extracellular matrix (Smolarczyk et al. 2012).

BP1 peptide binds to Flt-1 (VEGFR1) receptor, thus blocking the attachment of vascular endothelial growth factor and placenta growth factor (PIGF). Inability of PIGF protein to bind to Flt-1 receptors found on the surface of cancer cells inhibits the latter’s motility and may affect the formation of metastases (Taylor and Goldenberg 2007). This peptide can also act effectively upon tumor endothelial cells possessing Flt-1 receptor (Tarlolo et al. 2010). BP1 peptide has both anticancer properties (it inhibits proliferation of cancer cells) and is antiangiogenic.

Another therapeutic solution involves reinforcement of the immune system by applying interleukin (IL)-12. This cytokine activates secretion of interferon γ which, in turn, activates cytotoxic T lymphocytes and natural killer (NK) cells (Del Vecchio et al. 2007; Luedke et al. 2012; Uemura et al. 2010). Additionally, IL-12 inhibits angiogenesis, and formation of novel blood vessels (He et al. 2012; Rakhmilevich et al. 2004).

Materials and Methods

Plasmid pBCMGSNeo/IL-12

Plasmid pBCMGSNeo carrying a gene encoding murine IL-12 was obtained from Prof. H. Yamamoto (Osaka University, Japan). Murine IL-12 gene is composed of two subunits: p35 and p40 connected by cassette IRES. Gene of IL-12 cloned into BCMGSNeo (so-called Karasuyama’s expression vector), under the control of cytomegalovirus. Plasmid preparations were isolated using QIAGEN-EndoFree Giga Kit (Qiagen GmbH, Hilden, Germany).

Cell Culture

Murine melanoma B16-F10 and murine colon cancer C26 cells (ATCC) were propagated in RPMI 1640 supplemented with 10 % fetal bovine serum. Cell cultures were maintained in a standard 37 °C/5 % CO₂ incubator. Cells were passaged every 2–3 days.

Animals

Mice (6- to 8-week-old C57Bl/6 and BALB/c females) were from own animal facility. Consent for work with animals was obtained from the Local Ethics Commission (Silesian Medical University in Katowice).

DNA Fragmentation Studies: TUNEL Test

The studies were accomplished with In Situ Cell Death Detection Kit, TMR red (Roche Diagnostic GmbH, Germany). The tests were performed using gelatin-coated 8-well Chamber Slide plates. Aliquots of 2 × 10⁴ B16-F10 cells per well were seeded in 250-μL culture medium. After 24 h, the medium was replaced with: 10, 20, 40 μg D-K6L9 peptide or fresh medium.

Following a 3-h incubation, the treated cells were fixed with 4 % paraformaldehyde. Next, the specimens were incubated on ice for 2 min with 0.1 % Triton X-100. Positive control cells were digested with 200 μL DNase solution (10 min at 37 °C). A mixture of fluorescein-labeled nucleotides and TdT enzyme was then added to the wells. After 1-h incubation at 37 °C, the specimens were embedded in glycerogel and observed using a Nikon Eclipse 80i fluorescence microscope (λ = 540 nm). Micrographs were taken using NISElements AR image analysis software.

Hematoxylin and Eosin Staining

D-K6L9 peptide was injected intratumorally three times. Each time the treated mice received 100 μg D-K6L9 peptide in 100 μL physiological buffered saline (PBS⁻). Control mice were injected three times with PBS⁻ (100 μL per animal). Tumors were excised 24 h post-last injection. The collected material was fixed in 10 % formalin and embedded in paraffin. Five-μm-thick sections were then routinely stained with hematoxylin and eosin.
Immunohistochemical Identification of HMGB1 Protein in B16-F10 and C26 Tumors Following D-K6L9 Peptide Administration

Tumors were excised 24 h following D-K6L9 peptide administration. The collected material was fixed with 10% formalin, paraffin-embedded and cut into 5-μm-thick sections. The latter were deparaffinized and hydrated. Next, they were incubated with 0.3% H2O2 and boiled with citrate buffer (10 mM; pH 6.0). Blocking of unspecific sites was achieved with 2.5% horse serum. The sections were incubated for 1 h at RT using a primary rabbit anti-HMGB1 antibody [0.7 mg/mL; dilution 1:100; (Abcam, Cambridge, UK)] and with secondary horse anti-rabbit antibody conjugated to horseradish peroxidase (EC 1.11.1.7) from ImmPRESS™ REAGENT Anti-Rabbit Ig kit (Vector, USA). Next, the specimens were incubated with diaminobenzidine (DAB) from ImmPACT™ DAB kit. Brown-colored product was obtained as a result of enzymatic reaction. Finally, the specimens were dehydrated and were embedded using VectaMount™.

Animal Therapy Using D-K6L9 Peptide and Glycyrrhizin

C57Bl/6 mice were injected subcutaneously with 2 × 10^5 B16-F10 melanoma cells. On the seventh and eighth day following inoculation, a 100 μg aliquot of D-K6L9 peptide was injected intratumorally (in 100 μL PBS^-), whereas glycyrrhizin was injected intraperitoneally (2 mg/400 μL PBS^-). For the subsequent 4 days, only glycyrrhizin was administered. The experiment was repeated twice.

Animal Therapy Using D-K6L9 and BP1 Peptides

C57Bl/6 mice were injected subcutaneously with 2 × 10^5 B16-F10 melanoma cells. On the seventh and eighth day following inoculation, a 100 μg aliquot of D-K6L9 peptide was injected intratumorally (in 100 μL PBS^-). For the subsequent 3 days, BP1 peptide (in 100 μL H2O) was administered intratumorally. The experiment was repeated twice.

Animal Therapy with D-K6L9 Peptide and pBCMGSNeo/IL-12

C57Bl/6 or BALB/c mice were injected subcutaneously with 2 × 10^5 B16-F10 or C26 cells. On the seventh and eighth day following inoculation, a 100 μg aliquot of D-K6L9 peptide was injected intratumorally (in 100 μL PBS^-). For the subsequent 9 or 10 days pBCMGSNeo/IL-12 only was administered intratumorally (50 μg in 100 μL PBS^-). Control group mice received only plasmid DNA BCMGSNeo (empty plasmid), pBCMGSNeo/IL-12, D-K6L9 peptide, pBCMGSNeo (empty plasmid) with D-K6L9 peptide or PBS^- (doses and timing as in experimental groups). Plasmid DNA BCMGSNeo is the carrier of the therapeutic gene IL-12. To exclude the therapeutic effect of empty vector, pBCMGSNeo created two groups of control mice treated with: a combination of peptide and pBCMGSNeo (empty vector) and alone pBCMGSNeo (empty vector). The experiment was repeated three times.

Determination of CD8^+^, CD4^+^ and NK Cell Numbers in B16-F10 Melanoma Tumors During Therapy with D-K6L9 Peptide and pBCMGSNeo/IL-12

B16-F10 tumor material was collected for FACS analysis and single-cell suspension obtained with digestion mixture [0.5 mg/mL collagenase A, (Sigma Aldrich, MO, USA); 0.2 mg/mL hyaluronidase type V, (Sigma Aldrich, MO, USA); 0.02 mg/mL DNase I, (Roche Diagnostic GmbH, Germany); per each 0.25 g of tumor tissue]. Red blood cells were lysed using 0.15 M ammonium chloride solution (Sigma Aldrich, MO, USA). Dead cells were removed by centrifugation on Lympholyte-M gradients (Cedarlane, Canada). Level of T lymphocytes was determined in homogenous single-cell suspension. To identify the subpopulations of T lymphocytes, the following antibodies were used: PE-Cy™7-CD3e, PE-CD4 and FITC-CD8a (BD, Franklin Lakes, NJ, USA). NK cells were identified with an anti-mouse CD49b antibody (Biosciences, CA, USA). Gate parameters dividing negative from positive cells were chosen based on isotype antibody control probes (Jarosz et al. 2013).

Statistical Analysis

Differences between groups were determined by applying ANOVA followed by the Tukey’s post hoc test. A p value lower than 0.05 was considered statistically significant.

Results

D-K6L9 Peptide Does Not Cause DNA Fragmentation (TUNEL Test)

TUNEL test was performed on B16-F10 melanoma cells subjected to 3-h incubation with three different concentrations of D-K6L9 peptide (10, 20 or 40 μM), DNase (positive control) and on untreated cells (negative control). Positive control cells showed intense red fluorescence, thus confirming DNA fragmentation. Cells treated with D-K6L9 peptide, similarly as negative control cells, did not display
fluorescence. This shows that the examined peptide does not cause fragmentation at the times that have been studied (Fig. 1).

**D-K₆L₉ Peptide Increases Necrotic Regions in B16-F10 and C26 Tumors and Triggers HMGB1 Release**

Sections from D-K₆L₉ peptide-treated tumors were stained to show HMGB1 protein presence. As a result of treatment with this peptide, HMGB1 was released into cytoplasm, unlike in controls where the protein is confined to cell nucleus (Fig. 2).

**D-K₆L₉ Peptide and Glycyrrhizin Combination Inhibits Growth of B16-F10 Melanoma Tumors but Does Not Prolong Animal Survival**

D-K₆L₉ peptide combined with glycyrrhizin inhibits the growth of B16-F10 melanoma tumors as opposed to control groups of animals treated with peptide or glycyrrhizin only (Fig. 3). After cessation of therapy, tumor growth was resumed. Inhibition of tumor growth did not extend survival of the treated animals (data not shown).

**D-K₆L₉ and BP1 Peptide Combination Inhibits Growth of B16-F10 Melanoma Tumors but Does Not Prolong Animal Survival**

D-K₆L₉ and BP1 peptide combination inhibits the growth of B16-F10 melanoma tumors as opposed to control groups of animals treated only with either peptide (Fig. 4). After cessation of therapy, tumor growth was resumed. Inhibition of tumor growth did not extend survival of the treated animals (data not shown).

D-K₆L₉ Peptide Combined with IL-12 Inhibits Growth of B16-F10 Melanoma and C26 Murine Colon Carcinoma Tumors and Prolongs Animal Survival

D-K₆L₉ combined with pBCMGSNeo/IL-12 does inhibit the growth of B16-10 melanoma tumors as compared to control mice treated with PBS⁻, pBCMGSNeo (empty vector) pBCMGSNeo/IL-12, pBCMGSNeo (empty plasmid) with D-K₆L₉ peptide or D-K₆L₉ only (Fig. 5a). In 60% of cases, significant extension of survival period for combination treatment was observed (Fig. 5b). The increase in survival time of mice was associated with a complete loss of primary tumors (Fig. 5d). Similar effect was observed for C26 murine colon carcinoma tumors (Fig. 6a). In 50% of cases, significant extension of survival period for combination treatment was observed (Fig. 6b). The increase in survival time of mice was associated with a complete loss of primary tumors (Fig. 6d). This effect was observed even after 2 months following conclusion of therapy; mice were alive without any visible foci of B16-F10 melanoma tumors.

Combination of D-K₆L₉ Peptide with pBCMGSNeo/IL-12 Causes Increase in the Number of CD8⁺, CD4⁺ and NK Cells in B16-F10 Tumors

Mice treated with D-K₆L₉ peptide and pBCMGSNeo/IL-12 combination showed a significantly increased levels of tumor infiltrating CD8⁺ T lymphocytes and NK cells (Fig. 7). However, increases in the number of infiltrating cells CD4⁺ were not observed (Fig. 7). Animals treated with pBCMGSNeo (empty vector), pBCMGSNeo (empty plasmid) with D-K₆L₉, pBCMGSNeo/IL-12, peptide alone also showed increased numbers of T cells.
lymphocytes and NK cells but not to the same degree as in mice subjected to combinatorial treatment. The latter clearly activates both specific and nonspecific immune response.

**Discussion**

Peptides are among agents intensively investigated for anticancer properties. They show several advantages, such
as ease of synthesis, high degree of tumor tissues penetration or low immunogenicity. Among disadvantages is their relatively short half-time in circulation (Smolarczyk et al. 2009).

A synthetic D-K₆L₀ peptide selectively destroys cancer cells by damaging membrane structures (Papo et al. 2003). This leads to necrotic type of cell death (Papo et al. 2004).

Such a mechanism of cell death following exposure to this peptide can be inferred from lack of DNA fragmentation or lack of active caspase 3 (unpublished results), which confirms observations made by Papo et al. (2004).

In our experiments involving B16-F10 murine melanoma and C26 colon carcinoma tumors, we observed inhibited tumor growth (compared to control) only during therapy with the peptide. Papo et al. (2004, 2006) showed inhibitory effect of the peptide using 22RV1 and CL1 prostate tumor, as well as MDA-MB-231 breast tumor models.

Fig. 3 Effect of D-K₆L₀ peptide combination with glycyrrhizin on growth of B16-F10 murine melanoma tumors. On days 7 and 8 following inoculation of mice with B16-F10 cells, the animals were injected intratumorally with D-K₆L₀ peptide (100 µg/100 µL) and intraperitoneally with 2 mg glycyrrhizin. Next, for four consecutive days only glycyrrhizin was administered. Animals in control groups received D-K₆L₀ peptide, glycyrrhizin and PBS⁻ in same time sequences as those treated with combination therapy. Each group consisted of five animals. Differences in tumor volumes between mice that received D-K₆L₀ peptide and mice that received peptide and glycyrrhizin were statistically significant (*p < 0.009 Tukey post hoc analysis after ANOVA) on day 17 of the therapy.

Fig. 4 Effect of D-K₆L₀ peptide combination with BP1 peptide on growth of B16-F10 murine melanoma tumors. On days 7 and 8 following inoculation of mice with B16-F10 cells, the animals were injected intratumorally with D-K₆L₀ peptide (100 µg/100 µL). Next, for three consecutive days only BP1 peptide (100 µg/100 µL) was administered. Animals in control groups received D-K₆L₀ peptide, BP1 peptide and PBS⁻ in same time sequences as those treated with combination therapy. Each group consisted of five animals. Differences in tumor volumes between mice that received D-K₆L₀ peptide or BP1 peptide and mice that received both peptides were statistically significant (*p < 0.02 Tukey post hoc analysis after ANOVA) on day 14 of the therapy.
Following D-K_{6L9} peptide administration, we observed necrosis in tumor tissue as well as release of HMGB1 protein into extracellular space. The released HMGB1 activates division of surviving cancer cells, maintains inflammatory condition, stimulates the formation of tumor microenvironment towards angiogenesis. It thus contributes to sustained tumor growth (Smolarczyk et al. 2012; Tang et al. 2010). On the other hand, inflammatory condition induced by HMGB1 and stimulation of APC can be of significance for triggering specific immune response directed against cancer cells (Zhu et al. 2010). Numerous data have shown that tumor relapse is mediated by surviving cancer cells or cancer stem cells (CSC) (Baguley 2006; Diaz and Leon 2011). Despite the fact that CSCs constitute only a small percent of all cancer cells in a tumor, they are CSCs that are responsible for tumor chemoradioresistance (Bourguignon et al. 2008; Diaz and Leon 2011; Diehn et al. 2009; Holtz et al. 2005; Nandi 2006; Zhu et al. 2010).
et al. 2008; Shafee et al. 2008). This is explained by great resistance to apoptosis, elevated levels of repair proteins and ABC-type proteins mediating removal of toxins (Eyler and Rich 2008; Hirschmann-Jax et al. 2004).

It has been believed that effective therapy must lead to complete eradication of CSC (Blagosklonny 2005; Bonavia et al. 2011; Tang 2012). To achieve this, drugs are used that act independently of cell cycle (Diehn et al. 2009; Massard et al. 2006; Morrison et al. 2011), along with ABC protein inhibitors (Dean et al. 2005; Dylla et al. 2008; Ginestier et al. 2007) and immunotherapy (Cioffi et al. 2012; Lai et al. 2012; Ning et al. 2012; Parmiani et al. 2007; Pietra et al. 2009). A more promising strategy, however, consists of acting upon CSC niche which
includes endothelial cells forming tumor blood vasculature, macrophages, fibroblasts and immune system cells (Baguley 2006; Calabrese et al. 2007). To inhibit tumor relapse, two solutions are possible. First involves blocking HMGB1 activity which is conducive towards tumor growth. Second solution consists of enhancing immune system response directed against therapy-surviving cancer cells and CSC.

Our study was an attempt to develop a combination therapy involving D-K 6L9 peptide and agents that might strengthen its action. To achieve this, we used the following drugs: glycyrrhizin (an inhibitor of HMGB1), BP1 peptide (angiogenesis inhibitor) and IL-12 (a cytokine having immunostimulatory properties).

Glycyrrhizin administered intraperitoneally to mice previously treated with a peptide only inhibited growth of B16-F10 melanoma and C26 colon carcinoma tumors. A similar effect was observed when using a combination of glycyrrhizin with CAMEL peptide, which also triggers cell necrosis (Smolarczyk et al. 2010, 2012). In most likelihood tumor relapse that we observed following cessation of therapy was mediated by surviving cancer cells or CSC. Combination of glycyrrhizin with D-K6L9, as with CAMEL, is not very efficient. Irrespective of peptide used to induce necrosis, blocking HMGB1 only proved insufficient. To totally inhibit tumor growth, it is necessary to eliminate the remaining surviving cancer cells.

We further tested BP1 peptide which has both anticancer properties (it inhibits growth of cancer cells) and acts as an antiangiogenic (by inhibiting angiogenesis activated by HMGB1). In our opinion, due to its dual mode of action, this peptide matched very well the assumptions behind our combination strategy with D-K6L9. We observed inhibition of tumor growth only during the treatment, after which tumors invariably regrew. Similarly, like in the case of glycyrrhizin, surviving cancer cells or CSCs, not reached by BP1, are responsible. Since both therapies aimed at inhibiting activity of HMGB1 proved not very effective, we decided to check the combination involving D-K6L9 peptide and IL-12. The latter cytokine activates T lymphocytes and NK cells which infiltrate tumor mass and tissues in its vicinity and destroy cancer cells (Del Vecchio et al. 2007; Uemura et al. 2010).

Combination of D-K6L9 and IL-12 inhibits tumor growth and extends survival of the treated animals. In ca. 60 % of mice that harbored B16-F10 melanoma tumors and in 75 % of mice with C26 colon carcinoma tumors, total disappearance of tumors was observed.

A similar effect was observed when combining CAMEL peptide and plasmid DNA carrying IL-12 gene, where tumors disappeared in 60 % of mice bearing B16-F10 melanoma tumors (Smolarczyk et al. 2010). IL-12 combination with drugs that cause necrotic tumor cell death (CAMEL, D-K6L9) seems to be the best therapeutic option. IL-12 enhances response of the immune system, and activates NK cells to destroy residual tumor cells after which are responsible for tumor re-growth. In mice that were treated with combination therapy involving D-K6L9 and IL-12, infiltration of CD4+ , CD8+ and NK
cells was confirmed. Combination peptide with BP1 or glycyrrhizin only inhibits tumor regrowth by inhibiting angiogenesis. This is the reason why only temporary inhibition of tumor growth is observed after cessation of therapy. Cancer cells remaining alive after treatment with the peptide are responsible for this growth and are resistant to anti-angiogenic therapy. Therapeutic approach involving the use of anti-angiogenic therapy after radically destroying the tumor is ineffective.

IL-12 has pleiotropic properties: activates specific and non-specific response of the immune system but also has anti-angiogenic properties (Kilinc et al. 2006; Nanni et al. 1998). The use of IL-12 in combination with peptide not only inhibits angiogenesis but most importantly destroys survivors’ cancer cells, responsible for tumor regrowth. Effective cancer therapy should be based on a number of therapeutic solutions, for example, anti-angiogenic or anti-vascular therapy, but should essentially include immunotherapy.

To conclude, a therapeutic strategy consisting of joined administration of D-K6L9 peptide that induces necrosis of cancer cells with a cytokine activating immune system cells (IL-12) proved highly effective in inhibiting growth of two types of experimental tumors.

Acknowledgments This work was supported by the Polish Ministry of Science and Higher Education, grant No. N N401 018337. The study was carried out using capabilities provided by equipment bought for the purposes of the Project: “Silesian BIO-FARMA. Center for Biotechnology, Bioengineering, and Bioinformatics” co-financed by European Regional Development Fund within the framework of Innovative Economy Operational Programme 2007–2013.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Baguley BC (2006) Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anticancer Drug Discov 1:121–127
Blagosklonny MV (2005) Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4:1693–1698
Bonavia R, Inda MM, Cavenee WK et al (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055–4060
Bourguignon LY, Peyrollier K, Xia W et al (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651
Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82
Campana L, Bosurgi L, Rovere-Querini P (2008) HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 20:518–523
Cioffi M, Dorado J, Baueerle PA et al (2012) EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 18:465–474
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
Del Vecchio M, Bajetta E, Canova S et al (2007) Interleukin-12: biological properties and clinical application. Clin Cancer Res 13:4677–4685
Diaz A, Leon K (2011) Therapeutic approaches to target cancer stem cells. Cancer 3:3331–3352
Diehn M, Cho RW, Loboa NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783
Dylla SJ, Beviglia L, Park IK et al (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3:e2428
Ellerman JE, Brown CK, de Vera M et al (2007) Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 13:2836–2848
Eyler CE, Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26:2839–2845
Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567
He H, Fan P, Yin T et al (2012) Local delivery of recombinant adenovirus expressing hepatitis B virus X protein and interleukin-12 results in antitumor effects via inhibition of hepatoma cell growth and intervention of tumor microenvironment. Int J Mol Med 30:599–605
Hirschmann-Jax C, Foster AE, Wulf GG et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101:14228–14233
Holtz MS, Forman SJ, Bhatia R (2005) Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 19:1034–1041
Jaroz M, Jazowiecka-Rakus J, Cichoci T et al (2013) Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents. Gene Ther 20:262–273
Kilinc MO, Aulakh KS, Nair RE et al (2006) Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 177:6962–6973
Lai D, Wang F, Chen Y et al (2012) Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes. Cancer Immunol Immunother 61:979–989
Luedke E, Jaime-Raymírez AC, Bhave N et al (2012) Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery 152:431–440
Mader JS, Hoskin DW (2006) Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 15:933–946
Massard C, Deutsch E, Soria JC (2006) Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17:1620–1624
Morrison R, Schleicher SM, Sun Y et al (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011:941876

Nandi S, Ulasov IV, Tyler MA et al (2008) Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res 68:5778–5784

Nanni P, Rossi I, De Giovannini C et al (1998) Metastases interleukin-12 gene therapy of MHC-negative murine melanoma. Cancer Res 58:1225–1230

Ning N, Pan Qin, Fang Z et al (2012) Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 72:1853–1864

Papo N, Shai Y (2003) New lytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry 42:9346–9354

Papo N, Shahar M, Eisenbach L et al (2003) A novel lytic peptide composed of D-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem 278:21018–21023

Papo N, Braunstein A, Eshhar Z et al (2004) Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res 64:5779–5786

Papo N, Seger D, Makovitzki A et al (2006) Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res 66:5371–5378

Parmiani G, Russo V, Marrari A et al (2007) Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 13:5675–5679

Pietra G, Manzini C, Vitale M et al (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21:793–801

Rakhmilevich AL, Hooper AT, Hicklin DJ et al (2004) Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 3:969–976

Rovere-Querini P, Capobianco A, Scafidi P et al (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5:825–830

Shafee N, Smith CR, Wei S et al (2008) Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68:3243–3250

Smolarczyk R, Cichoń T, Szala S (2009) Peptides: a new class of anticancer drugs. Postepy Hig Med Dośw 63:360–368

Smolarczyk R, Cichoń T, Kamysz W et al (2010) Anticancer effects of CAMEL peptide. Lab Invest 90:940–952

Smolarczyk R, Cichon T, Matuszczak S et al (2012) The role of glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Arch Immunol Ther Exp 60:391–399

Tang DG (2012) Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22:457–472

Tang D, Kang R, Zeh HJ et al (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799:131–140

Taylor AP, Goldenberg DM (2007) Role of placenta growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 70:1804–1813

Uemura A, Takehara T, Miyagi T et al (2010) Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol Immunother 59:453–463

Wang C, Fei G, Liu Z et al (2012) HMGB1 was a pivotal synergistic effector for CpG oligonucleotide to enhance the progression of human lung cancer cells. Cancer Biol Ther 13:727–736

Yang H, Tracey KJ (2010) Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799:149–156

Yang H, Wang H, Czura ChJ et al (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1–8

Zhu S, Li W, Ward MF et al (2010) High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 9:60–72